School of Medicine

Research from the McKelvey School of Engineering highlights the interaction between MRI and focused ultrasound with microbubbles.

Julie O’Neal, assistant professor of medicine at the School of Medicine, received a $250,000 award from the International Myeloma Society. The award will be used to develop novel immunotherapy treatments for multiple myeloma, a common blood cancer.

A research team at Washington University School of Medicine has identified potential new treatment targets for Alzheimer’s disease, as well as existing drugs that have therapeutic potential against these targets.

The Division of Physician-Scientists at the School of Medicine has selected four physicians for its second class of Dean’s Scholars. The program provides up to two years of financial support and mentorship to aspiring, early-career physician-scientists, along with dedicated time for conducting laboratory research.

A multidisciplinary team led by McKelvey School of Engineering researchers will probe the dynamic brain cell mechanisms on which artificial intelligence is based with a nearly $4 million grant from the U.S. Army.

Antibiotic sales soared during India’s first surge of COVID-19, suggesting that the drugs were inappropriately used to treat mild and moderate COVID-19 infections, according to research led by the School of Medicine. Such overuse increases the risk for drug-resistant infections worldwide.

Philip R. O. Payne, director of the Institute for Informatics at the School of Medicine, has been elected a fellow of the International Academy of Health Sciences Informatics.

Kristen Kroll, professor of developmental biology at the School of Medicine, has received a four-year $2.1 million grant from the National Institutes of Health (NIH) for her project on human interneuron progenitor specification.

Researchers at Washington University School of Medicine have shown in preclinical studies that a natural killer cell-based immunotherapy could be effective against solid tumors such as melanoma.

A study from School of Medicine researchers, published in the journal Nature, has found evidence that the immune response to the first two COVID-19 vaccines authorized by the FDA is both strong and potentially long-lasting.